The study of relationship between intratumoral/bile microbiome and chemoresistance/prognosis in patients with biliary tract cancer
Not Applicable
Recruiting
- Conditions
- Biliary tract cancer
- Registration Number
- JPRN-UMIN000050587
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1) combination with other malignancies (2) cholangitis at sample collection (3) unclear about history of antibiotic use within 3 months at sample collection (4) unsuitable for inclusion at the discretion of the physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relationship between intratumoral microbiome and progression-free survival in patients with biliary tract cancer
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does intratumoral microbiome diversity correlate with chemoresistance mechanisms in biliary tract cancer patients?
What bile microbiome signatures predict prognosis in JPRN-UMIN000050587 observational biliary tract cancer study?
Are specific microbial taxa associated with response to standard-of-care chemotherapy in cholangiocarcinoma subtypes?
What adverse event patterns emerge from microbiome alterations during biliary tract cancer treatment?
How might microbiome-targeted therapies synergize with conventional chemotherapies for biliary tract malignancies?